UK markets close in 1 hour 23 minutes

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0400+1.6880 (+124.85%)
As of 8:33AM BST. Market open.
Full screen
Previous close1.3520
Open1.3520
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.3600 - 1.3600
52-week range1.3600 - 1.3600
Volume9,010
Avg. volumeN/A
Market cap189.616M
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)-0.0650
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Is Transgene (EPA:TNG) Using Debt In A Risky Way?
    Simply Wall St.

    Is Transgene (EPA:TNG) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Is Transgene SA's (EPA:TNG) ROE Of 35% Impressive?
    Simply Wall St.

    Is Transgene SA's (EPA:TNG) ROE Of 35% Impressive?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
    Business Wire

    Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

    Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, a therapeutic vaccine based on the myvac™ technology and powered by NEC’s cutting-edge AI capabilities. In these Phase 1 trials, TG4050 is being administered to patients with head and neck cancer who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy. Transgene’s highly innovative myvac™ technology allows the generation of a virus-based immunotherapy within a very short time frame while encoding patient-specific mutations identified and selected by NEC’s Neoantigen Prediction System.